Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Clinical trials for type 1 spinal muscular atrophy (SMA) necessitate robust natural history data.
• Understanding disease progression is vital for evaluating therapeutic interventions.

Purpose of the Study:

• To assess functional changes in type 1 SMA infants using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) scale.
• To analyze longitudinal nutritional and respiratory data in relation to disease progression.
• To correlate SMN2 gene copy number with clinical phenotype and disease trajectory.

Main Methods:

• A cohort of 20 type 1 SMA infants was studied.
• Patients were stratified into three subgroups based on phenotype severity and age of onset.
• Functional status was measured using the CHOP INTEND scale; nutritional and respiratory data were collected longitudinally.
• SMN2 copy number was assessed for each patient.

Main Results:

• Significant differences in baseline scores and progression trajectories were observed across the three subgroups (p=0.0001).
• Infants with the most severe phenotype exhibited the lowest initial CHOP INTEND scores and the most rapid decline.
• A milder phenotype and slower disease progression were associated with higher SMN2 copy numbers (three copies).
• Two SMN2 copies were present across all severity subgroups.

Conclusions:

• Phenotype severity and age of onset significantly impact functional decline in type 1 SMA.
• The CHOP INTEND scale effectively differentiates disease progression rates among SMA subtypes.
• SMN2 copy number is a key genetic factor influencing SMA phenotype severity and progression.